ECApproval

Pfizer Announces Hympavzi European Commission Approval: A Milestone for Hemophilia Care

By Regulatory Intelligence Desk
13 May 2026

The recent Hympavzi European Commission Approval marks a milestone for the hemophilia community, introducing the first once-weekly anti-TFPI therapy for patients with inhibitors in the EU.

Tag: ECApproval

Pfizer Announces Hympavzi European Commission Approval: A Milestone for Hemophilia Care

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement